Cargando…
Warfarin and Antibiotics: Drug Interactions and Clinical Considerations
Warfarin administration poses a notable challenge in clinical practice due to the increased susceptibility of patients to major bleeding, particularly when co-administered with other medications capable of modulating its metabolic pathways. Among these medications, antibiotics have been recognized a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455514/ https://www.ncbi.nlm.nih.gov/pubmed/37629518 http://dx.doi.org/10.3390/life13081661 |
_version_ | 1785096470497591296 |
---|---|
author | Vega, Alexis J. Smith, Caitlin Matejowsky, Hannah Grace Thornhill, Katherine J. Borne, Grant E. Mosieri, Chizoba N. Shekoohi, Sahar Cornett, Elyse M. Kaye, Alan D. |
author_facet | Vega, Alexis J. Smith, Caitlin Matejowsky, Hannah Grace Thornhill, Katherine J. Borne, Grant E. Mosieri, Chizoba N. Shekoohi, Sahar Cornett, Elyse M. Kaye, Alan D. |
author_sort | Vega, Alexis J. |
collection | PubMed |
description | Warfarin administration poses a notable challenge in clinical practice due to the increased susceptibility of patients to major bleeding, particularly when co-administered with other medications capable of modulating its metabolic pathways. Among these medications, antibiotics have been recognized as potential agents that can either induce or inhibit cytochrome P450-2C9, thereby impacting the effects of warfarin. A wealth of evidence from numerous studies consistently supports an elevated risk of serious bleeding in patients concurrently receiving antibiotics and warfarin therapy. This narrative review elucidates the intricate interactions between warfarin and various antibiotic classes. Notably, significant increases in the International Normalized Ratio (INR) were observed among warfarin-treated patients receiving penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides. Conversely, investigations have also demonstrated a reduction in INR levels in patients on warfarin when exposed to rifampin, a potent inducer of cytochrome P-450. Intriguingly, cephalosporin antibiotics and amoxicillin/clavulanate, despite not interfering with the cytochrome P450 system, exhibited a positive association with increased INR values. The findings of this narrative review underscore the importance of diligent monitoring in patients on warfarin requiring concomitant antibiotic therapy, as this surveillance strategy proves pivotal in mitigating the risk of major bleeding complications. Additionally, for patients necessitating cytochrome P450 inhibitors such as penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides, the consideration of dose reduction in warfarin therapy may confer substantial benefits in reducing the occurrence of major bleeding events. Similarly, patients who are co-administered rifampin alongside warfarin necessitate vigilant monitoring, with a potential need for escalating warfarin doses to counteract the risk of a hypercoagulable state. |
format | Online Article Text |
id | pubmed-10455514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104555142023-08-26 Warfarin and Antibiotics: Drug Interactions and Clinical Considerations Vega, Alexis J. Smith, Caitlin Matejowsky, Hannah Grace Thornhill, Katherine J. Borne, Grant E. Mosieri, Chizoba N. Shekoohi, Sahar Cornett, Elyse M. Kaye, Alan D. Life (Basel) Review Warfarin administration poses a notable challenge in clinical practice due to the increased susceptibility of patients to major bleeding, particularly when co-administered with other medications capable of modulating its metabolic pathways. Among these medications, antibiotics have been recognized as potential agents that can either induce or inhibit cytochrome P450-2C9, thereby impacting the effects of warfarin. A wealth of evidence from numerous studies consistently supports an elevated risk of serious bleeding in patients concurrently receiving antibiotics and warfarin therapy. This narrative review elucidates the intricate interactions between warfarin and various antibiotic classes. Notably, significant increases in the International Normalized Ratio (INR) were observed among warfarin-treated patients receiving penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides. Conversely, investigations have also demonstrated a reduction in INR levels in patients on warfarin when exposed to rifampin, a potent inducer of cytochrome P-450. Intriguingly, cephalosporin antibiotics and amoxicillin/clavulanate, despite not interfering with the cytochrome P450 system, exhibited a positive association with increased INR values. The findings of this narrative review underscore the importance of diligent monitoring in patients on warfarin requiring concomitant antibiotic therapy, as this surveillance strategy proves pivotal in mitigating the risk of major bleeding complications. Additionally, for patients necessitating cytochrome P450 inhibitors such as penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides, the consideration of dose reduction in warfarin therapy may confer substantial benefits in reducing the occurrence of major bleeding events. Similarly, patients who are co-administered rifampin alongside warfarin necessitate vigilant monitoring, with a potential need for escalating warfarin doses to counteract the risk of a hypercoagulable state. MDPI 2023-07-30 /pmc/articles/PMC10455514/ /pubmed/37629518 http://dx.doi.org/10.3390/life13081661 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vega, Alexis J. Smith, Caitlin Matejowsky, Hannah Grace Thornhill, Katherine J. Borne, Grant E. Mosieri, Chizoba N. Shekoohi, Sahar Cornett, Elyse M. Kaye, Alan D. Warfarin and Antibiotics: Drug Interactions and Clinical Considerations |
title | Warfarin and Antibiotics: Drug Interactions and Clinical Considerations |
title_full | Warfarin and Antibiotics: Drug Interactions and Clinical Considerations |
title_fullStr | Warfarin and Antibiotics: Drug Interactions and Clinical Considerations |
title_full_unstemmed | Warfarin and Antibiotics: Drug Interactions and Clinical Considerations |
title_short | Warfarin and Antibiotics: Drug Interactions and Clinical Considerations |
title_sort | warfarin and antibiotics: drug interactions and clinical considerations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455514/ https://www.ncbi.nlm.nih.gov/pubmed/37629518 http://dx.doi.org/10.3390/life13081661 |
work_keys_str_mv | AT vegaalexisj warfarinandantibioticsdruginteractionsandclinicalconsiderations AT smithcaitlin warfarinandantibioticsdruginteractionsandclinicalconsiderations AT matejowskyhannahgrace warfarinandantibioticsdruginteractionsandclinicalconsiderations AT thornhillkatherinej warfarinandantibioticsdruginteractionsandclinicalconsiderations AT bornegrante warfarinandantibioticsdruginteractionsandclinicalconsiderations AT mosierichizoban warfarinandantibioticsdruginteractionsandclinicalconsiderations AT shekoohisahar warfarinandantibioticsdruginteractionsandclinicalconsiderations AT cornettelysem warfarinandantibioticsdruginteractionsandclinicalconsiderations AT kayealand warfarinandantibioticsdruginteractionsandclinicalconsiderations |